Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Fonseca

Showing results (1-10 of 358) with videos related to

Pageof 36
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Use of genetic markers in multiple myelomaRafael Fonseca
Hematology. American Society of Hematology. Education Program|November 21, 2007
Strategies for risk-adapted therapy in myelomaRafael Fonseca
Blood|December 14, 2011
Innovation in myeloma treatments PARP excellence!Rafael Fonseca
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Assessment of MRD in patients with hematologic malignancies: clinical insightsRafael Fonseca
The New England Journal of Medicine|December 14, 2012
How physicians interpret research funding disclosuresRafael Fonseca
The New England Journal of Medicine|March 20, 2010
Continuing medical education--limiting industry's influenceRafael Fonseca
Oncology (Williston Park, N.Y.)|November 29, 2013
Non-secretory myeloma: clinical and biologic implicationsRafael Fonseca
Hematology (Amsterdam, Netherlands)|April 18, 2012
Frontline treatment of multiple myelomaRafael Fonseca
Blood Reviews|February 8, 2011
Plasma cell leukemiaFlavio Albarracin, Rafael Fonseca
Seminars in Oncology|October 19, 2013
Myeloma: classification and risk assessmentRafael Fonseca, Jorge Monge
Pageof 36

Showing results (1-10 of 358) with videos related to

Sort By:
Pageof 36
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Use of genetic markers in multiple myelomaRafael Fonseca
Hematology. American Society of Hematology. Education Program|November 21, 2007
Strategies for risk-adapted therapy in myelomaRafael Fonseca
Blood|December 14, 2011
Innovation in myeloma treatments PARP excellence!Rafael Fonseca
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
Assessment of MRD in patients with hematologic malignancies: clinical insightsRafael Fonseca
The New England Journal of Medicine|December 14, 2012
How physicians interpret research funding disclosuresRafael Fonseca
The New England Journal of Medicine|March 20, 2010
Continuing medical education--limiting industry's influenceRafael Fonseca
Oncology (Williston Park, N.Y.)|November 29, 2013
Non-secretory myeloma: clinical and biologic implicationsRafael Fonseca
Hematology (Amsterdam, Netherlands)|April 18, 2012
Frontline treatment of multiple myelomaRafael Fonseca
Blood Reviews|February 8, 2011
Plasma cell leukemiaFlavio Albarracin, Rafael Fonseca
Seminars in Oncology|October 19, 2013
Myeloma: classification and risk assessmentRafael Fonseca, Jorge Monge
Pageof 36